1-(3-氨基-5-硝基-苯基)乙酮 | 5456-49-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3-氨基-5-硝基-苯基)乙酮
• 英文名称: 5-amino-3-nitroacetophenone
• 英文别名: 5-Nitro-3-amino-acetophenon；5-Amino-3-nitroacetophenon；1-(3-amino-5-nitrophenyl)ethanone；3-acetyl-5-nitroaniline；1-(3-Amino-5-nitro-phenyl)-aethanon
• CAS: 5456-49-5
• 化学式: C₈H₈N₂O₃
• mdl: MFCD01754405
• 分子量: 180.163
• InChiKey: YRRSEQCBYUJZPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  88.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2922399090

反应信息

• 作为反应物：
  描述：

  1-(3-氨基-5-硝基-苯基)乙酮 在 吡啶 、 盐酸 、 溶剂黄146 、 copper(ll) bromide 、 sodium nitrite 作用下， 以 二氯甲烷 、 水 、 乙酸乙酯 、 丙酮 为溶剂， 生成
  参考文献：
  名称：

  Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization

  摘要：

  The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by crystal structure analysis, we reversed the sulfonamide group and identified a new binding mode. A structure-activity relationship study on this new series led to several potent BRD4 inhibitors with IC50 of about 0.05-0.1 mu M in FP binding assay and GI50 of 0.1-0.3 mu M in cell based assays. To complete the lead-like assessment of this series, we further checked its effects on BRD4 downstream protein c-Myc, investigated its selectivity among five different bromodomain proteins, as well as the metabolic stability test, and reinforced the utility of 2-thiazolidinone scaffold as BET bromodomain inhibitors in novel anticancer drug development.

  DOI：

  10.1021/jm501504k
• 作为产物：
  描述：

  3′,5′-二硝基乙酰苯 在 盐酸 、 tin(ll) chloride 作用下， 生成 1-(3-氨基-5-硝基-苯基)乙酮
  参考文献：
  名称：

  Berend; Heymann, Journal fur praktische Chemie (Leipzig 1954), 1904, vol. <2> 69, p. 466

  摘要：

  DOI：

文献信息

• Zinc Mediated Friedel-Crafts Acylation in Solvent-Free Conditions under Microwave Irradiation
  作者：Rajive Gupta、Satya Paul、Puja Nanda、André Loupy

  DOI：10.1055/s-2003-42485

  日期：——

  Zn powder is found to catalyze the Friedel-Crafts acylation of aromatic compounds with acyl halides efficiently under microwave irradiation in solvent-free conditions. Activated substrates undergo acylation predominantly at the para-position. The Zn powder can be re-used up to six times after simple washing with diethyl ether and dilute HCl.

  锌粉被发现能在无溶剂条件下，通过微波辐射高效催化芳香化合物与酰氯的傅-克酰基化反应。活化后的底物主要在邻位进行酰基化。经过用乙醚和稀盐酸简单洗涤后，锌粉可被重复使用多达六次。
• Novel tricyclic compounds and drug compositions containing same
  申请人：ASAHI KASEI KOGYO KABUSHIKI KAISHA

  公开号：US20030139475A1

  公开（公告）日：2003-07-24

  Compounds having a &bgr;-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc., represented by a general formula (I) and salts thereof, and a process for producing these, and their intermediates, wherein R represents hydrogen or methyl; R 1 represents hydrogen, halogen, hydroxy, benzyloxy, amino, or hydroxymethyl; R 2 represents hydrogen, hydroxymethyl, NHR 3 , SO 2 NR 4 R 4′ , or nitro; R 6 represents hydrogen or lower alkyl; and X represents nitrogen, R 9 represents hydrogen, one of R 7 and R 8 represent hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy.

  具有&bgr;-3肾上腺素受体激动剂的化合物，可用于治疗和预防糖尿病、肥胖症、高脂血症等疾病，其通式表示为(I)，并且包括其盐，以及制备这些化合物和其中间体的方法。其中，R代表氢或甲基；R1代表氢、卤素、羟基、苄氧基、氨基或羟甲基；R2代表氢、羟甲基、NHR3、SO2NR4R4′或硝基；R6代表氢或低碳基；X代表氮；R9代表氢；R7和R8中的一个代表氢，而另一个代表氢、氨基、乙酰氨基或羟基。
• NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0882707A1

  公开（公告）日：1998-12-09

  Compounds represented by general formula (I) or salts thereof, a process for producing the same, and intermediates therefor, wherein R represents hydrogen or methyl; R1 represents hydrogen, hologeno, hydroxy, benzyloxy, amino, or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4, or nitro; R6 represents hydrogen or lower alkyl; and X represents nitrogen, oxygen, sulfur, or methylene, provided that when X represents nitrogen, oxygen, or sulfur, then R9 represents hydrogen, one of R7 an R8 represents hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy, and when X represents methylene, then R7 and R8 each represents hydrogen and R9 represents hydrogen, amino, etc. They have a β-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc.

  通式(I)所代表的化合物或其盐类，以及生产该化合物或其盐类的工艺和中间体，其中R代表氢或甲基；R1代表氢、囟素、羟基、苄氧基、氨基或羟甲基；R2代表氢、羟甲基、NHR3、SO2NR4R4或硝基；R6代表氢或低级烷基；X代表氮、氧、硫或亚甲基，但当X代表氮、氧或硫时，R9代表氢，R7和R8中的一个代表氢，另一个代表氢、氨基、乙酰氨基或羟基；当X代表亚甲基时，R7和R8各自代表氢，R9代表氢、氨基等。它们具有β-3肾上腺素受体激动剂的作用，可作为治疗和预防糖尿病、肥胖症、高脂血症等的药物。
• NOVEL TRICYCLIC COMPOUNDS HAVING SATURATED RINGS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0997458A1

  公开（公告）日：2000-05-03

  Compounds represented by general formula (I) or their salts, having β3 -adrenoceptor agonism and being efficacious when employed in drugs for treating and preventing diabetes, obesity, hyperlipemia, etc. wherein R represents hydrogen or methyl; R1 represents hydrogen, halogeno, hydroxy, benzyloxy, amino or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4', or nitro (wherein R3 represents hydrogen, methyl, SO2R5, formyl or CONHR6'; R5 represents lower alkyl, benzyl or NR4R4'; R4 and R4' may be the same or different and each represents hydrogen, lower alkyl or benzyl; and R6' represents hydrogen or lower alkyl); R6 represents hydrogen or lower alkyl; n is 1 or 2; X represents secondary nitrogen, oxygen or sulfur; and when n is 1, then one of R7 and R8 represents hydrogen while another represents hydrogen, amino, acetylamino or hydroxy, or when n is 2, then R8 represents hydrogen while R7 represents hydrogen, amino, acetylamino or hydroxy.

  通式(I)所代表的化合物或其盐类，具有 β3-肾上腺素受体激动作用，在用于治疗和预防糖尿病、肥胖症、高血脂症等药物时具有疗效。其中 R 代表氢或甲基；R1 代表氢、卤素、羟基、苄氧基、氨基或羟甲基；R2 代表氢、羟甲基、NHR3、SO2NR4R4'或硝基（其中 R3 代表氢、甲基、SO2R5、甲酰基或 CONHR6'；R5 代表低级烷基、苄基或 NR4R4'；R4 和 R4'可以相同或不同，各自代表氢、低级烷基或苄基；和 R6' 代表氢或低级烷基）；R6 代表氢或低级烷基；n 为 1 或 2；X 代表仲氮、氧或硫；当 n 为 1 时，则 R7 和 R8 中的一个代表氢，而另一个代表氢、氨基、乙酰氨基或羟基，或当 n 为 2 时，则 R8 代表氢，而 R7 代表氢、氨基、乙酰氨基或羟基。
• Preparation of allylic aromatic compounds
  申请人：NYCOMED IMAGING AS

  公开号：EP1013636A1

  公开（公告）日：2000-06-28

  A process for the preparation of an allylic aromatic compound in which an aromatic amine is reacted first with a nitrite and then with an allylic olefin having an eliminatable terminal substituent. Novel allylic derivatives of disubstituted benzene compounds are also described.

  一种制备烯丙基芳香化合物的工艺，其中芳香胺首先与亚硝酸盐反应，然后与具有可消除末端取代基的烯丙基烯烃反应。还描述了二取代苯化合物的新型烯丙基衍生物。